ERBB2 and non-small cell lung carcinoma: The phase II DESTINY-Lung01 trial included 91 patients with HER2-mutated, treated NSCLC who received DS-8201 and reported an ORR of 55%, median PFS of 8.2 months, and median OS of 17.8 months [133].